BMJ Open · 2020 · 28 citations · 17 references
MedicinePharmacoeconomicsPreventive MedicineCost-effectiveness AnalysisDisease PreventionHealth Technology AssessmentCardiovascular DiseaseCardiovascular Disease PreventionCardiovascular RiskCardiovascular Risk ReductionEconomic EvaluationHealth Impact AssessmentCardiovascular ConditionsCardiovascular Disease ManagementCardiovascular Risk DetectionCost Savings EvaluationLife-years Gained ModelingNet Benefit AnalysisNet Health BenefitOutcome Measures
OBJECTIVES: To estimate the cost savings and health benefits of improving detection of individuals at high risk of cardiovascular disease (CVD) in England, to determine to which patient subgroups these benefits arise, and to compare different strategies for subsequent management. DESIGN: An economic analysis using the School for Public Health Research CVD Prevention Model. SETTING: England 2018. PARTICIPANTS: Adults aged 16 and older with one or more high cardiovascular risk conditions, including hypertension, diabetes, non-diabetic hyperglycaemia, atrial fibrillation, chronic kidney disease and high cholesterol. INTERVENTIONS: Detection of 100% of individuals with CVD high risk conditions compared with current levels of detection in England. Detected individuals are assumed to be managed either according to current levels of care or National Institute of Health and Care Excellence (NICE) guidelines. MAIN OUTCOME MEASURES: Incremental and cumulative costs, savings, quality adjusted life years (QALYs), CVD cases, and net monetary benefit, from a UK NHS and Personal Social Services perspective. RESULTS: £68 billion could be saved, 4.9 million QALYs gained and 3.4 million cases of CVD prevented over 25 years if all individuals in England with the six CVD high risk conditions were diagnosed and subsequently managed at current levels. Additionally, if all detected individuals were managed according to NICE guidelines, total savings would be £61 billion, 8.1 million QALYs would be gained and 5.2 million CVD cases prevented. Most benefits come from detection of high cholesterol in the short term and diabetes in the long term. CONCLUSIONS: Substantial cost savings and health benefits would accrue if all individuals with conditions that increase CVD risk could be diagnosed, with detection of undiagnosed diabetes producing greatest benefits. Ensuring all conditions are managed according to NICE guidelines would further increase health benefits. Projected cost-savings could be invested in developing acceptable and cost-effective solutions for improving detection and management.
17
Joep Perk, Guy De Backer, H. Gohlke et al. · European Heart Journal · 2012 · 8.5K citations · Full text
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo Piepoli, Arno W. Hoes, Stefan Agewall et al. · European Heart Journal · 2016 · 6.5K citations · Full text
European Cardiovascular Disease Statistics 2017
Elizabeth Wilkins, Lloyd R. Wilson, Kremlin Wickramasinghe et al. · Bristol Research (University of Bristol) · 2017 · 522 citations
Alison Hayes, José Leal, Alastair Gray et al. · Diabetologia · 2013 · 500 citations · Full text
Pharmacy, Chronic Disease Control, Clinical Epidemiology +12